Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03563950 · ClinicalTrials.gov registry record · Phase 1
An Investigational Study to Evaluate the Effect of Rifampin on the Singe Dose of Experimental Medication BMS-986224 in Healthy Participants
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT03563950 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 42 participants.
The verdict
NCT03563950, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate if the blood levels of experimental medication BMS-986224 will be changed when given together with Rifampin, an antibiotic that affects specific enzymes involved with the breakdown of BMS-986224.
Interventions
- DRUG Rifampin
- DRUG BMS-986224
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2018-06-01 |
| Est. Completion | 2018-07-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03563950
The ClinicalTrials.gov registry entry for NCT03563950 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rifampin is the first listed.
NCT03563950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03563950 about?
NCT03563950 is a clinical study titled "An Investigational Study to Evaluate the Effect of Rifampin on the Singe Dose of Experimental Medication BMS-986224 in Healthy Participants". The purpose of this study is to investigate if the blood levels of experimental medication BMS-986224 will be changed when given together with Rifampin, an antibiotic that affects specific enzymes involved with the breakdown of BMS-986224.
What is the current status of trial NCT03563950?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2018-06-01. Estimated completion is 2018-07-27.
What interventions are being tested in trial NCT03563950?
The interventions under investigation include: Rifampin (DRUG), BMS-986224 (DRUG).
Who is sponsoring clinical trial NCT03563950?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.